Tag Archive for: Drug development

The U.S. Food and Drug Administration approved nearly 50% more novel drugs in 2023 than in 2022, putting it back on pace with historical levels, an improvement analysts and investors said could lead to increased investment in biotech firms.

Biomedical research, the bedrock of medical advancements on Earth, has always been a maze of challenges. From the complexities of human biology to the unpredictability of diseases, researchers are in a constant battle with variables that can alter the course of a study. But what if there was a way to sidestep some of these Earth-bound limitations? This is where space, the next frontier in clinical research, comes into play.

The company is putting a stop to a trial investigating what it calls the Opdualag combination, a pairing of Opdivo (nivolumab) and relatlimab, in patients with microsatellite stable metastatic colorectal cancer.

The Novo Nordisk Foundation, which controls drug maker Novo Nordisk, said it would commit up to 1.8 billion Danish crowns ($265 million) to setting up an initiative aimed at improving vaccines for respiratory diseases.

It is the biggest change to existing medical laws in two decades, aiming to ensure all Europeans have access to innovative treatments and drugs.

Clinical trials continue to experience a paucity of diversity, but it will take a multipronged approach to infuse DEI into research.

In its most basic form, market access means ensuring patients can physically get a product. Sounds simple, right?

Following a nine-month review, the Biden administration will issue a framework for the National Institutes of Health to implement so-called “march-in rights” under the Bayh-Dole Act of 1980.

In recent years, J&J has pumped hundreds of millions of dollars into its artificial intelligence (AI) capabilities, according to the WSJ, including bringing on some 6,000 data science and digital specialists and erecting a “cutting-edge” research facility in the San Francisco Bay Area, which it opened in September 2022.

Predictions from Pamela Tenaerts, M.D., chief scientific officer and Alison Holland, executive GM of customer value, Medable.